Aug 2026
The addition of evolocumab vs ezetimibe to statin therapy for coronary plaque regression and sd-LDL reduction in patients with ultrahigh-risk ASCVD.
In patients with ultrahigh-risk ASCVD, evolocumab was more effective than ezetimibe in promoting coronary plaque regression and the importance of targeting sd-LDL to reduce residual cardiovascular risk is underscored.
Xiao-Ping Li, Lin Yang, X. Zhou et al.
· Journal of Clinical Lipidolo... · 0 citations